Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

(2013) Susan E. Shoaf et al.   KIDNEY INTERNATIONAL

Vasopressin, Copeptin, and Renal Concentrating Capacity in Patients with Autosomal Dominant Polycystic Kidney Disease without Renal Impairment

(2012) D. Zittema et al.   Clinical Journal of the American Society of Nephrology

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

(2012) Susan E. Shoaf et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation

(2012) Thien Anh Ho et al.   KIDNEY INTERNATIONAL

Aquaretic Treatment in Polycystic Kidney Disease

(2012) Rudolf P. Wüthrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

(2011) Vicente E. Torres et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

(2011) Susan E. Shoaf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers

(2011) Seong Ryul Kim et al.   CARDIOVASCULAR DRUGS AND THERAPY

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

(2011) E. Higashihara et al.   Clinical Journal of the American Society of Nephrology

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

(2011) Susan E. Shoaf et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

(2011) Maria V. Irazabal et al.   KIDNEY INTERNATIONAL

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug

(2011) E. Meijer et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects

(2011) Ming-Yang Chang et al.   NEPHRON CLINICAL PRACTICE

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

(2010) Susan E. Shoaf et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

(2010) Andreas L. Serra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

(2010) Gerd Walz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autosomal dominant polycystic kidney disease: Emerging concepts of pathogenesis and new treatments

(2009) W. E. BRAUN   CLEVELAND CLINIC JOURNAL OF MEDICINE

A Case for Water in the Treatment of Polycystic Kidney Disease

(2009) V. E. Torres et al.   Clinical Journal of the American Society of Nephrology

Autosomal dominant polycystic kidney disease: the last 3 years

(2009) Vicente E. Torres et al.   KIDNEY INTERNATIONAL

Autosomal Dominant Polycystic Kidney Disease

(2008) Jared J. Grantham   NEW ENGLAND JOURNAL OF MEDICINE

Vasopressin Antagonists in Polycystic Kidney Disease

(2008) Vicente E. Torres   SEMINARS IN NEPHROLOGY

Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease

(2007) X. Wang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY